KIR2DL4 and breast cancer: A recent study demonstrated that KIR2DL4 synergized with FcRγ to augment NK cell activation and degranulation, whereas the interaction of HLA-G with KIR2DL4 attenuated NK cell cytotoxicity in HER2-positive breast cancer [158].